MP38-16 SURVIVAL BENEFIT OF NEPHROURETERECTOMY IN SYSTEMIC THERAPY EXPOSED METASTATIC UPPER TRACT URINARY UROTHELIAL CARCINOMA PATIENTS.

MLA

Morra, Simone, et al. “Mp38-16 Survival Benefit of Nephroureterectomy in Systemic Therapy Exposed Metastatic Upper Tract Urinary Urothelial Carcinoma Patients.” Journal of Urology, vol. 211, May 2024, p. e648. EBSCOhost, https://doi.org/10.1097/01.JU.0001008700.92603.b1.16.

APA

Morra, S., Incesu, R.-B., Scheipner, L., Baudo, A., Jannello, L. M. I., Siech, C., De Angelis, M., Tian, Z., Creta, M., Califano, G., Ruvolo, C. C., Saad, F., Shariat, S. F., Chun, F., De Cobelli, O., Musi, G., Briganti, A., Tilki, D., Ahyai, S., & Carmignagni, L. (2024). Mp38-16 Survival Benefit of Nephroureterectomy in Systemic Therapy Exposed Metastatic Upper Tract Urinary Urothelial Carcinoma Patients. Journal of Urology, 211, e648. https://doi.org/10.1097/01.JU.0001008700.92603.b1.16

Chicago

Morra, Simone, Reha-Baris Incesu, Lukas Scheipner, Andrea Baudo, Letizia M. I. Jannello, Carolin Siech, Mario De Angelis, et al. 2024. “Mp38-16 Survival Benefit of Nephroureterectomy in Systemic Therapy Exposed Metastatic Upper Tract Urinary Urothelial Carcinoma Patients.” Journal of Urology 211 (May): e648. doi:10.1097/01.JU.0001008700.92603.b1.16.